New obesity drug retatrutide tested in major trial to find best dosing strategy
NCT ID NCT07357415
First seen Jan 23, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This phase 3 trial is testing different ways to increase the dose of retatrutide, a weight-loss drug, in 600 people with obesity or overweight who do not have type 2 diabetes. The study lasts about 113 weeks and aims to find the safest and most effective dosing schedule for weight loss and related health improvements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advanced Research Institute
Ogden, Utah, 84405, United States
-
Aggarwal and Associates Limited
Brampton, L6T 0G1, Canada
-
Arizona Research Center
Phoenix, Arizona, 85053, United States
-
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, 02115, United States
-
C.I.C. Mauricie inc.
Trois-Rivières, G8T 7A1, Canada
-
CAMC Institute for Academic Medicine
Charleston, West Virginia, 25304, United States
-
CARDIAMET Investigaciones Médicas
Buenos Aires, C1014ACP, Argentina
-
Canadian Phase Onward
Toronto, M3J 0K2, Canada
-
Care Access - Huntington Beach
Huntington Beach, California, 92648, United States
-
Care Access - Raleigh
Raleigh, North Carolina, 27607, United States
-
Cedar Health Research
Dallas, Texas, 75251, United States
-
Cedar Health Research - Fort Worth
Fort Worth, Texas, 76132, United States
-
Cedar Health Research - Texas Native Health
Dallas, Texas, 75235, United States
-
Centro Médico Viamonte
Buenos Aires, C1120AAC, Argentina
-
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, C1056ABI, Argentina
-
Cicemo Srl
Buenos Aires, 1424, Argentina
-
Diex Recherche Inc. Division Joliette
Joliette, J6E 6A9, Canada
-
Diex Recherche Inc. Division Quebec
Québec, G1V 4T3, Canada
-
Diex Recherche Inc. Division Sherbrooke
Sherbrooke, J1L 0H8, Canada
-
Dominion Medical Associates, Inc.
Richmond, Virginia, 23219, United States
-
Dr. Anil K. Gupta Medicine Professional Corporation
Toronto, M9V 4B4, Canada
-
Encore Medical Research - Weston
Weston, Florida, 33331, United States
-
Great Lakes Research Group, Inc.
Bay City, Michigan, 48706, United States
-
Los Angeles Institute for Metabolic Research
Los Angeles, California, 90015, United States
-
Med Trust Research
Courtice, L1E 2J5, Canada
-
Milestone Research Inc.
London, N5W 6A2, Canada
-
Monroe Biomedical Research - Louisville
Louisville, Kentucky, 40213, United States
-
NYC Research INC
Long Island City, New York, 11106, United States
-
New Horizon Research Center
Miami, Florida, 33165, United States
-
New Phase Research and Development
Knoxville, Tennessee, 37909, United States
-
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, 96817, United States
-
Stat Research S.A.
Buenos Aires, C1023AAB, Argentina
-
Velocity Clinical Research, Dallas
Dallas, Texas, 75230, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States
-
Winterberry Research Inc.
Hamilton, L8J 0B6, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Retatrutide (a drug injected under the skin)
What this could lead to
If successful, this could provide a more tolerable way to achieve significant weight loss with retatrutide, potentially reducing obesity-related health risks.
What could go wrong
This is a phase 3 trial, but results may not apply to everyone. Side effects from the drug are possible, and weight regain may occur after stopping treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.